Regentis Biomaterials
Pioneering innovative hydrogel solutions for tissue regeneration through advanced scientific development
Pioneering innovative hydrogel solutions for tissue regeneration through advanced scientific development
Regentis Biomaterials is a pioneering company dedicated to the development and commercialization of unique hydrogels for tissue regeneration. With their primary technology being the biodegradable hydrogel known as Gelrin™, crafted from polyethylene glycol diacrylate and denatured fibrinogen, the company integrates the durability of synthetic materials with the biological functionality of natural substances. Dr. Dror Seliktar originally created the Gelrin hydrogel platform at Technion University. Regentis Biomaterials' leading product, GelrinC™, is currently undergoing clinical trials for treating articular cartilage lesions after extensive preclinical and safety evaluations. Founded in 2004, the company operates in the Biotechnology, Health Care, and Medical Devices industries. Their most recent investment of €3.12M came in the form of a grant from EASME - EU Executive Agency for SMEs on 01 January 2019.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | €3.12M | 1 | EASME - EU Executive Agency for SMEs | 01 Jan 2019 |
| Series D | $15.00M | 5 |
|
07 Feb 2016 |
| Series C | $10.00M | 3 |
|
14 May 2012 |
| Series B | $7.50M | 1 |
|
21 Aug 2007 |
| Seed Round | Unknown | - | 01 Sep 2004 |
No recent news or press coverage available for Regentis Biomaterials.
We care about your data, and we'd love to use cookies make your experience better.
